Buprenorphine/naloxone - Orexo

Drug Profile

Buprenorphine/naloxone - Orexo

Alternative Names: Naloxone/buprenorphine - Orexo; OX-219; PKX-219; Zubsolv

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaKodex
  • Developer Orexo
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 15 Sep 2017 Committee for Medicinal Products for Human Use issued a positive opinion for buprenorphine and naloxone sublingual tablet for Opioid abuse in European Union (Sublingual) in September 2017
  • 01 Mar 2017 Orexo initiates litigation against Actavis over generic versions of Suboxone® and Subutex in USA
  • 16 Nov 2016 Orexo receives patent allowance for buprenorphine/naloxone in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top